Browse > Article
http://dx.doi.org/10.22722/KJPM.2021.29.2.86

Management of Weight Gain and Obesity Associated With Antipsychotics  

Lee, Na-Hyun (Department of Psychiatry, Konyang University Hospital)
Lee, Jae-Chang (Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation)
Publication Information
Korean Journal of Psychosomatic Medicine / v.29, no.2, 2021 , pp. 86-94 More about this Journal
Abstract
Objectives : The risk of weight gain is high when using antipsychotic drugs, and the prevalence of obesity in people with mental illness is high. Obesity management in psychiatric patients is important because obesity causes various complications and lowers treatment adherence and quality of life. Methods : In this review, we summarized the management strategies for obesity that can occur when using antipsychotic drugs through a web search. Results : Evaluate obesity-related risk factors and related indicators from the beginning of treatment, and conduct regular monitoring. If an antipsychotic drug is used and obesity is induced, a change to a drug with a low metabolic risk may be attempted. Sufficient interventions are also needed on the need to manage obesity, a healthy diet, and exercises in patients and their families. If weight loss is not achieved and obesity-related complications are associated, the use of anti-obesity drugs may be considered. Pharmacological treatment approaches should be carefully considered. Conclusions : Non-pharmacological and pharmacological therapies can be applied to manage weight gain and obesity caused by the use of antipsychotic drugs. When using anti-obesity drugs, the characteristics of mental disorders, drug safety, and drug interactions should be considered.
Keywords
Obesity management; Weight gain; Antipsychotics;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Dutia R, Meece K, Dighe S, Kim AJ, Wardlaw SL. β-endorphin antagonizes the effects of α-MSH on food intake and body weight. Endocrinology 2012;153:4246-4255.   DOI
2 Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 2006;14:212-222.   DOI
3 Naughton M, Dinan TG, Scott LV. Corticotropin-releasing hormone and the hypothalamic-pituitary-adrenal axis in psychiatric disease. Vol. 124. 1st ed. Elsevier B.V.; 2014.
4 Hasnain M, Vieweg WVR, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med 2012;124:154-167.   DOI
5 Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels SR, Wadden TA, Tsai AG, Hu FB, Jakicic JM, Ryan DH, Wolfe BM, Inge TH. The science of obesity management: an endocrine society scientific statement. Endocr Rev 2018;39:79-132.   DOI
6 Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997;65; 79-85.   DOI
7 Vandenberghe F, Najar-Giroud A, Holzer L, Conus P, Eap CB, Ambresin AE. Second-generation antipsychotics in adolescent psychiatric patients: metabolic effects and impact of an early weight change to predict longer term weight gain. J Child Adolesc Psychopharmacol 2018;28:258-265.   DOI
8 Mula M, Trimble MR, Lhatoo SD, Sander JWAS. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003;44:659-663.   DOI
9 Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N, Underwood P, Park KH, Seufert J, Kang ES, Sternthal E, Karagiannis A, Mantzoros CS. Pharmacotherapy of type 2 diabetes: an update. Metabolism 2018; 78:13-42.   DOI
10 Kastin AJ, Akerstrom V, Pan W. Interactions of glucagonlike peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002;18:7-14.   DOI
11 Baptista T, Kin NMKNY, Beaulieu S, De Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35:205-219.   DOI
12 Bruins J, Jorg F, Bruggeman R, Slooff C, Corpeleijn E, Pijnenborg M. The effects of lifestyle interventions on (longterm) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a metaanalysis. PLoS One 2014;9:1-20.
13 Chalmer T, Almdal TP, Vilsboll T, Knop FK. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer. Expert Opin Drug Saf 2015;14:171-180.   DOI
14 Kim BY, Kang SM, Kang JH, Kim KK, Kim B, Kim SJ, Kim YH, Kim JH, Kim JH, Nam GE, Park JY, Son JW, Shin HJ, Oh TJ, Lee H, Jeon EJ, Chung S, Hong YH, Kim CH. Current long-term pharmacotherapies for the management of obesity. J Obes Metab Syndr 2020;29:99-109.   DOI
15 Son JW, Kim S. Comprehensive review of current and upcoming anti-obesity drugs. Diabetes Metab J 2020;44:802-818.   DOI
16 Hoffmann VP, Case M, Stauffer VL, Jacobson JG, Conley RR. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, control. J Clin Psychopharmacol 2010;30:656-660.   DOI
17 Prevalence of Obesity and Incidence of Obesity-Related Comorbidities in Koreans Based on National Health Insurance Service Health Checkup Data 2006-2015 (J Obes Metab Syndr 2018;27:46-52). Vol. 27. 2020.
18 Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003;108:324-332.   DOI
19 De Hert M, Detraux J, Van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8:114-126.   DOI
20 van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014;38:784-793.   DOI
21 Farr OM, Tsoukas MA, Triantafyllou G, Dincer F, Filippaios A, Ko BJ, Mantzoros CS. Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study. Metabolism 2016;65:945-953.   DOI
22 Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011;7;507-516.   DOI
23 Scaini G, Quevedo J, Velligan D, Roberts DL, Raventos H, Walss-Bass C. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. Eur Neuropsychopharmacol 2018;28:369-380.   DOI
24 O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, Brett J, Cancino AP, Wilding JPH. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes, Obes Metab 2017;19:1529-1536.   DOI
25 Menard C, Pfau ML, Hodes GE, Russo SJ. Immune and neuroendocrine mechanisms of stress vulnerability and resilience. Neuropsychopharmacology 2017;42:62-80.   DOI
26 Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf 2015;14:73-96.   DOI
27 Grimm JJ. Interaction of physical activity and diet: implications for insulin- glucose dynamics. Public Health Nutr 1999;2: 363-368.   DOI
28 Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, Zhao J, Liu Y, Fang Y, Zhang Y, Xie P. Atypical Antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol 2015;18:pyv060.   DOI
29 Driessen J, Baik SH, Zhang Y. Trends in off-label use of second-generation antipsychotics in the medicare population from 2006 to 2012. Psychiatr Serv 2016;67:898-903.   DOI
30 Vandenberghe F, Gholam-Rezaee M, Saigi-Morgui N, Delacretaz A, Choong E, Solida-Tozzi A, Kolly S, Thonney J, Gallo SF, Hedjal A, Ambresin AE, von Gunten A, Conus P, Eap CB. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 2015;76:e1417-e1423.   DOI
31 Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66:51-57.   DOI
32 Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 2017;13:2231-2241.   DOI
33 Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005;27:1930-1941.   DOI
34 Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003; 23:595-600.   DOI
35 Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012;140:159-168.   DOI
36 Ebdrup BH, Knop FK, Ishoy PL, Rostrup E, Fagerlund B, Lublin H, Glenthoj B. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med 2012;10:1-7.   DOI
37 Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrom CT, Correll CU, Vilsboll T, Fink-Jensen A. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand 2019;139:26-36.   DOI
38 Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab 2014;25:593-600.   DOI
39 Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 2003;75:255-260.   DOI
40 Lu ML, Wang TN, Lin TY, Shao WC, Chang SH, Chou JY, Ho YF, Liao YT, Chen VCH. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 2015; 58:47-50.   DOI
41 Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008;105:175-187.   DOI
42 de Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012;367:1397-1406.   DOI
43 Bonfioli E, Berti L, Goss C, Muraro F, Burti L. Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry 2012;12:78.   DOI
44 Hasnain M, Vieweg WVR. Do we truly appreciate how difficult it is for patients with schizophrenia to adapt a healthy lifestyle? Acta Psychiatr Scand 2011;409-410.
45 Stanhope KL, Havel PJ. Fructose consumption: recent results and their potential implications. Ann New York Acad Sci 2010;15-24.
46 Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.   DOI
47 Turk Y, Theel W, Kasteleyn MJ, Franssen FME, Hiemstra PS, Rudolphus A, Taube C, Braunstahl GJ. High intensity training in obesity: a Meta-analysis. Obes Sci Pract 2017;3:258-271.   DOI
48 Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110-120.   DOI
49 Loh C, Meyer J, Leckband S. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry 2006;18:23-31.
50 Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, Wang Z, Elraiyah T, Brito JP, Mauck KF, Lababidi MH, Prokop LJ, Asi N, Wei J, Fidahussein S, Montori VM, Murad MH. Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:363-370.   DOI
51 Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008;193:101-107.   DOI
52 Korean Society for the Study of Obesity. Guideline for the management of obesity;2020. p.97.
53 Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag 2007;3;817-821.
54 Werneke U, Taylor D, Sanders TAB. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 2002;17:145-160.   DOI
55 Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, Wald R, Garg AX. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011;703-704.
56 Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014;63:2985-3023.   DOI
57 Evers SS, van Vliet A, van Vugt B, Scheurink AJW, van Dijk G. A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers. Psychoneuroendocrinology 2016;66:101-110.   DOI
58 Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS, Hansen G, Grove KL, Pyke C, Raun K, Schaffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014;124:4473-4488.   DOI
59 Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med 2018;130:173-182.   DOI
60 Buysschaert B, Aydin S, Morelle J, Hermans MP, Jadoul M, Demoulin N. Weight loss at a high cost: orlistat-induced late-onset severe kidney disease. Diabetes Metab 2016;42: 62-64.   DOI
61 Lyu X, Du J, Zhan G, Wu Y, Su H, Zhu Y, Jarskog F, Zhao M, Fan X. Naltrexone and Bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia. Front Pharmacol 2018;9:7-11.   DOI
62 Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 2008;103:94-103.   DOI
63 Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, Eronen M, Rasanen P. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:706-711.   DOI
64 Tchoukhine E, Takala P, Hakko H, Raidma M, Putkonen H, Rasanen P, Terevnikov V, Stenberg JH, Eronen M, Joffe G. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 2011; 72:326-330.   DOI
65 Greig SL, Keating GM. Naltrexone ER/bupropion ER: a review in obesity management. Drugs 2015;75:1269-1280.   DOI
66 Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Perez-Iglesias R, Martinez-Garcia O, Perez-Pardal T, Ramirez-Bonilla ML, Crespo-Facorro B. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006;67:1253-1260.   DOI
67 Castelnovo A, Zambrelli E, Canevini MP, Cavallotti S, Scarone S, D'Agostino A. Occipital seizures and visual pseudohallucinations associated with the addition of bupropion to clozapine: a case report. J Clin Psychopharmacol 2015;97-99.
68 Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 2010;376:595-605.   DOI
69 Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21:935-943.   DOI
70 Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36:4022-4029.   DOI
71 Schmitz A, Botner B, Hund M. Bupropion with clozapine: case reports of seizure after coadministration. J Pharm Pract 2021;34:497-502.   DOI
72 Benazzi F. Depression induced by orlistat (Xenical). Can J Psychiatry 2000;87.
73 Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000;198.
74 Moon SJ, Kim KH, Song JY, Paik J. The Causes of Death of the Institutionalized Population of Kkottongnae: Comparison between Severe Mental Illness Group (SMI) and Non-Severe Mental Illness Group (Non-SMI), Korean J Biol Psychiatry 2009;16:198-204.
75 Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou AE, Mantzoros CS. Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism 2019;92:170-192.   DOI
76 Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006;47: 614-625.   DOI
77 Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95;297-308.   DOI
78 Narayanaswami V, Dwoskin LP. Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther 2017;170:116-147.   DOI
79 Lee SH, Liu CY, Yang YY. Schizophreniform-like psychotic disorder induced by phentermine: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61:44-47.
80 Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, Maj M, McIntyre RS, Naber D, Newcomer JW, Olfson M, Osby U, Sartorius N, Lieberman JA. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008;514-519.
81 Bak M, Fransen A, Janssen J, Van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014;9:10-12.
82 Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med 2010;40:187-200.   DOI
83 Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-1773.   DOI
84 Yang YC, Yeh TC, Liang CS. A case of recurrent seizures: drug-drug interaction between low-dose clozapine and extended-release bupropion. Aust N Z J Psychiatry 2019;175-176.
85 Balf G, Stewart TD, Whitehead R, Baker RA. Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Prim Care Companion J Clin Psychiatry 2008;10:15-24.   DOI
86 Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci 2018;1411:106-119.   DOI
87 Caixas A, Albert L, Capel I, Rigla M. Naltrexone sustainedrelease/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther 2014; 8:1419-1427.
88 Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 2009;16:354-364.   DOI
89 Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012;20:330-342.   DOI
90 Monami M, Nreu B, Scatena A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab 2017;19:1233-1241.   DOI
91 Citrome L, Volavka J. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 2004;27.
92 Gierisch JM, Nieuwsma JA, Bradford DW, Wilder CM, Mann-Wrobel MC, McBroom AJ, Wing L, Musty MD, Chobot MM, Hasselblad V, Williams JW Jr. Interventions to improve cardiovascular risk factors in people with serious mental illness. Duke Evidence-based Practice Center: Agency for Healthcare Research and Quality (US), Rockville (MD);2013.
93 Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004;27: 155-161.   DOI
94 Dossabhoy NR, McRight S, Sangha B, Khan S, Adgeh C. Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation. J Louisiana State Med Soc Off Organ Louisiana State Med Soc 2013;165:283-285.
95 Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, chjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrom CT, Correll CU, Vilsboll T, Fink-Jensen A. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2017;74: 719-728.   DOI
96 Kwak S, Youn T, Lee NY, Chung IW, Kim SH. Phentermine, phendimetrazine psychotic disorder induced by appetite suppressants, phentermine. Korean J Biol Psychiatry 2017; 24:134-141.
97 Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo ALC, Martinotti G, Mazza M, Perna G, Carano A, De Bartolomeis A, Di Giannantonio M, De Berardis D. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 2016;15:1329-1347.   DOI
98 Kolotkin RL, Corey-Lisle PK, Crosby RD, Swanson JM, Tuomari AV, L'Italien GJ. Mitchell JE. Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity 2008;16:749-754.   DOI
99 Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. Br Med J 2007;335:1194-1199.
100 Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007;1-163.
101 Hill AJ. Psychological aspects of obesity. Psychiatry 2005;4:26-30.   DOI
102 Yarborough BJH, Leo MC, Stumbo S, Perrin NA, Green CA. STRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications. BMC Psychiatry 2013;13:1-11.   DOI
103 Jo HS, Wang SM, Kim JJ. Recurrent psychosis after phentermine administration in a young female: a case report. Clin Psychopharmacol Neurosci 2019;17:130-213.   DOI
104 Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53:S53-S67.
105 Homola J, Hieber R. Combination of venlafaxine and phentermine/topiramate induced psychosis: a case report. Ment Heal Clin 2018;8:95-99.   DOI
106 Ellinger LK, Ipema HJ, Stachnik JM. Efficacy of metformin and topiramate in prevention and treatment of secondgeneration antipsychotic-induced weight gain. Ann Pharmacother 2010;44:668-679.   DOI
107 Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-2600.   DOI